The median duration of neoadjuvant therapy differed significantly between the two groups, with KIT-exon 11 mutated GIST patients undergoing an average of 8.8 months (range 0.2–31.3 months) of treatment compared to 5.3 months (range 0.5–21.0 months) for patients with non-KIT-exon 11 mutated GIST (p < 0.001). The gene discussed is KIT; the disease is gastrointestinal stromal tumor.